Myeloid Therapeutics Funding: $195M Raised, Series A (2026)
Myeloid Therapeutics is based in Cambridge, MA. It has raised $195M in total funding. Latest round: Series A.
Myeloid Therapeutics funding overview
Myeloid Therapeutics is based in Cambridge, MA. Myeloid Therapeutics has raised $195M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series A announced in May 2026. The round record for Myeloid Therapeutics runs through 2026; nothing later has been disclosed. Investors on record include Newpath Partners, ARCH Venture Partners, Hatteras Venture Partners, Moore Strategic Ventures, 8VC, Alexandria Venture Investments. 6 distinct backers are named across the disclosed rounds.
Frequently asked about Myeloid Therapeutics funding
How much has Myeloid Therapeutics raised?
Myeloid Therapeutics has raised $195M in total disclosed funding across the rounds on record.
Who has invested in Myeloid Therapeutics?
Newpath Partners, ARCH Venture Partners, Hatteras Venture Partners, Moore Strategic Ventures, 8VC, Alexandria Venture Investments are named among the investors backing Myeloid Therapeutics.
What was the latest Myeloid Therapeutics funding round?
The most recent disclosed round is a Series A, announced in May 2026.
Where is Myeloid Therapeutics based?
Myeloid Therapeutics is based in Cambridge, MA.
When did Myeloid Therapeutics last raise?
The last disclosed Myeloid Therapeutics round closed in May 2026 at Series A.
Every Myeloid Therapeutics figure above comes from filings and announced rounds in the StartupFundraising company database and is revised as new rounds are recorded. The lists below compare companies in Cambridge at a similar stage.
